Abcentra is excited to announce our upcoming participation in the 2024 Imperial Vulnerable Patient and Plaque Meeting, taking place from September 23-25 in Seville, Spain. This prestigious event will gather nearly 80 internationally renowned researchers to explore groundbreaking developments in cardiovascular care, with a special focus on vulnerable patients and advanced imaging techniques.
On Day 1, we will kick things off with Chief Science Officer Jan Nilsson’s presentation “Orticumab – An antioxidised LDL Antibody on the treatment of Atherosclerosis” during Session 1: Novel Targets in Atherosclerosis, led by Ramzi Khamis and Patrick Serruys.
On Day 2, we are honored to have Charalambous Antoniades represent Abcentra in the morning program. He will present “The Effect of Orticumab on Coronary Inflammation” during Session 1: The Future of Coronary CT, led by Jason Tarkin and Patrick Serruys.
We look forward to sharing our latest research and contributing to this vital discussion on the future of coronary imaging.
Spots for this free event are limited, so we encourage those interested to sign up in advance to secure a place. Don’t miss this unique opportunity to engage with global leaders in cardiovascular research and explore the cutting edge of coronary imaging.
